CARE™ Case HL Discussion Series

Questions and approaches in frontline advanced Hodgkin Lymphoma

05 Oct 2022

Introduction

 

Dr. Alison Moskowitz, Memorial Sloan Kettering Cancer Centre, NY, spoke with CARE™ Hematology Faculty lead, Dr. Peter Anglin, Stronach Regional Cancer Centre, on approaches in frontline advanced Hodgkin Lymphoma.

Discussion focused on:

· How does age figure into decision making with BV-AVD regimen?

· Is there a patient for upfront escBEACOPP?

· Approaches to Brentuximab neuropathy (Grade 2)

Video Navigation

 

[0:30] Question 1: How does age figure into decision making with BV-AVD regimen?

[3:28] Question 2: Is there a patient for upfront escBEACOPP?

[6:25] Discussion point: Approaches to Brentuximab neuropathy (Grade 2)

Related Content

 

Case HL Discussion Series

Drs. Anglin and Moskowitz consider treatment of Advanced Hodgkin Lymphoma with a case discussion.


Case

  • 52-year-old woman
  • Presents with advanced stage cHL
    • Considered stage 4 advanced cHL
    • ECOG performance status 0-1

Variation on Case

  • 21 vs 52-year-old woman

Supplemental Discussion

  • BV-AVD – efficacy and safety

 

You can access this link by clicking here.

CARE™ discussion series is supported by Seagen Canada.